ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) approval of its Epic™ Stented Tissue Valve with Linx™ AC Technology. Identical in design to the company’s Biocor™ Valve, which currently leads the tissue valve industry in U.S. market share growth, the Epic Valve also incorporates patented anti-calcification technology designed to protect against tissue mineralization, or hardening. An estimated 100,000 Americans undergo heart valve replacement annually and the majority of them receive tissue valves.
